About this Research Topic
Protein homeostasis involves in maintaining the structural, functional stability and quantitative level of intracellular proteins. The dysregulation of protein homeostasis often leads to multiple pathological conditions and disease progression. The modulation of protein homeostasis occurs through the control of protein synthesis, degradation or stabilization. The development of protein homeostasis modulators has made an impact in the medicine research, including molecular glues, proteolysis targeting chimeras (PROTACs) and deubiquitinase targeting chimeras (DUBTACs), they have been demonstrated unique mechanism advantages over traditional inhibitors, antagonists or agonists. It is expected to bring about a technological revolution in the treatment of disease.
Currently, protein homeostasis modulators, especially protein degraders, have been devoted to treating hematologic malignancies and lymphoma. The molecular glues such as lenalidomide and thalidomide have been approved in clinic. Although the modulators possess great potential against hematologic malignancies and lymphoma, their medicinal development is still limited and underlying mechanisms remain to be understood. Therefore, with this research topic, our goal is to encourage scientists to share their studies about hematologic malignancies and lymphoma treatments with protein homeostasis modulators. We also aim to gather research include new degraders design, novel modulating strategies, and mechanisms investigation.
In total, the aim of the current Research Topic is to cover recent and novel research trends in the field of protein homeostasis in hematologic malignancies and lymphoma. Areas to be covered in this Research Topic may include, but are not limited to:
• Novel/improved methodologies for regulating protein homeostasis
• The discovery and development of new protein degraders for the treatment of hematologic malignancies and lymphoma
• Mechanism investigation for treating hematologic malignancies and lymphoma
• Discovery of new targeting chimeras for the control of protein synthesis, degradation or stabilization
Currently, protein homeostasis modulators, especially protein degraders, have been devoted to treating hematologic malignancies and lymphoma. The molecular glues such as lenalidomide and thalidomide have been approved in clinic. Although the modulators possess great potential against hematologic malignancies and lymphoma, their medicinal development is still limited and underlying mechanisms remain to be understood. Therefore, with this research topic, our goal is to encourage scientists to share their studies about hematologic malignancies and lymphoma treatments with protein homeostasis modulators. We also aim to gather research include new degraders design, novel modulating strategies, and mechanisms investigation.
In total, the aim of the current Research Topic is to cover recent and novel research trends in the field of protein homeostasis in hematologic malignancies and lymphoma. Areas to be covered in this Research Topic may include, but are not limited to:
• Novel/improved methodologies for regulating protein homeostasis
• The discovery and development of new protein degraders for the treatment of hematologic malignancies and lymphoma
• Mechanism investigation for treating hematologic malignancies and lymphoma
• Discovery of new targeting chimeras for the control of protein synthesis, degradation or stabilization
Keywords: Protein homeostasis, Hematologic malignancies, Lymphoma, Modulators, Degraders
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
